Adjuvant treatment for renal cell carcinoma

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 6, 2006, Pages 705-720

  Lam, John S ^a   Belldegrun, Arie S ^a   Figlin, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant therapy; Carbonic anhydrase IX; Heat shock protein; Monoclonal antibody; Renal cell carcinoma; Tumour associated antigen

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; B7 ANTIGEN; BCG VACCINE; CD14 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; CIMETIDINE; FLUOROURACIL; GAMMA INTERFERON; GLUCOCORTICOID RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; INTERLEUKIN 2; INTERLEUKIN 4; MEDROXYPROGESTERONE ACETATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; STEROID RECEPTOR; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ADOPTIVE IMMUNOTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL STUDY; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DRUG DOSE REGIMEN; FEVER; HUMAN; IMMUNOTHERAPY; INJECTION SITE REACTION; KIDNEY ARTERY EMBOLIZATION; KIDNEY CARCINOMA; NEPHRECTOMY; NONHUMAN; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR LOCALIZATION;

ADJUVANTS, PHARMACEUTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY, ACTIVE; KIDNEY NEOPLASMS;

EID: 33645827972     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.6.705     Document Type: Review

References (90)

1. JEMAL A, MURRAY T, WARD E et al.: Cancer statistics, 2005. CA Cancer J. Clin. (2005) 55(1):10-30.
2. PISANI P, PARKIN DM, BRAY F, FERLAY J: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer (1999) 83(1):18-29.
3. GOLIMBU M, JOSHI P, SPERBER A et al.: Renal cell carcinoma: survival and prognostic factors. Urology (1986) 27(4):291-301.
4. LAM JS, LEPPERT JT, FIGLIN RA, BELLDEGRUN AS: Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr. Urol. Rep. (2005) 6(1):7-18.
5. LAM JS, SHVARTS O, LEPPERT JT, PANTUCK AJ, FIGLIN RA, BELLDEGRUN AS: Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J. Urol. (2005) 174(2):466-472.
6. LAM JS, SHVARTS O, LEPPERT JT, FIGLIN RA, BELLDEGRUN AS: Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J. Urol. (2005) 173(6):1853-1862.
7. LAM JS, BELLDEGRUN AS, FIGLIN RA: Advances in immune-based therapies of renal cell carcinoma. Expert Rev. Anti-Cancer Ther. (2004) 4(6):1081-1096.
8. SANDOCK DS, SEFTEL AD, RESNICK MI: A new protocol for the follow up of renal cell carcinoma based on pathological stage. J. Urol. (1995) 154(1):28-31.
9. LEVY DA, SLATON JW, SWANSON DA, DINNEY CP: Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J. Urol. (1998) 159(4):1163-1167.
10. LJUNGBERG B, ALAMDARI FI, RASMUSON T, ROOS G: Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. (1999) 84(4):405-411.
11. JANZEN NK, KIM HL, FIGLIN RA, BELLDEGRUN AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North Am. (2003) 30(4):843-852.
12. STEPHENSON AJ, CHETNER MP, ROURKE K et al.: Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J. Urol. (2004) 172(1):58-62.
13. RABINOVITCH RA, ZELEFSKY MJ, GAYNOR JJ, FUKS Z: Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. J. Clin. Oncol. (1994) 12(1):206-212.
14. SKINNER DG, COLVIN RB, VERMILLION CD, PFISTER RC, LEADBETTER WF: Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer (1971) 28(5):1165-1177.
15. ZISMAN A, PANTUCK AJ, DOREY F et al.: Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. (2001) 19(6):1649-1657.
16. PANTUCK AJ, ZISMAN A, DOREY F et al.: Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J. Urol. (2003) 169(6):2076-2083.
17. FRANK I, BLUTE ML, CHEVILLE JC et al.: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. (2002) 168(6):2395-2400.
18. LEIBOVICH BC, BLUTE ML, CHEVILLE JC et al.: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (2003) 97(7):1663-1671.
19. SENGUPTA S, LOHSE CM, LEIBOVICH BC et al.: Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer (2005) 104(3):511-520.
20. LAM JS, SHVARTS O, SAID JW et al.: Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. Cancer (2005) 103(12):2517-2525.
21. KONONEN J, BUBENDORF L, KALLIONIEMI A et al.: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. (1998) 4(7):844-847.
22. LAM JS, BELLDEGRUN AS, FIGLIN RA: Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy. Clin. Cancer Res. (2004) 10(18 Pt 2):6304S-6309S.
23. KIM HL, SELIGSON D, LIU X et al.: Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res. (2004) 10(16):5464-5471.
24. SHVARTS O, SELIGSON D, LAM J et al.: p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J. Urol. (2005) 173(3):725-728.
25. ZISMAN A, PANTUCK AJ, WIEDER J et al.: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. (2002) 20(23):4559-4566.
26. PATARD JJ, KIM HL, LAM JS et al.: Use of the university of california los angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J. Clin. Oncol. (2004) 22(16):3316-3322.
27. ZIELINSKI H, SZMIGIELSKI S, PETROVICH Z: Comparison of preoperative embolization followed by radical nephrectomy with radical nephrectomy alone for renal cell carcinoma. Am. J. Clin. Oncol. (2000) 23(1):6-12.
28. RICHES EW, GRIFFITHS IH, THACKRAY AC: New growths of the kidney and ureter. Br. J. Urol. (1951) 23:297-356.
29. MAKAREWICZ R, ZARZYCKA M, KULINSKA G, WINDORBSKA W: The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma (1998) 45(6):380-383.
30. KJAER M, IVERSEN P, HVIDT V et al.: A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J. Urol. Nephrol. (1987) 21(4):285-289.
31. KJAER M, FREDERIKSEN PL, ENGELHOLM SA: Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int. J. Radiat. Oncol. Biol. Phys. (1987) 13(5):665-672.
32. BOJAR H, MAAR K, STAIB W: The endocrine background of human renal cell carcinoma. IV Glucocorticoid receptors as possible mediators of progestogen action. Urol. Int. (1979) 34(5):330-338.
33. CHEN L, WEISS FR, CHAICHIK S, KEYDAR I: Steroid receptors in human renal carcinoma. Isr. J. Med. Sci. (1980) 16(11):756-760.
34. TAKENAWA J, KANEKO Y, OKUMURA K et al.: Inhibitory effect of dexamethasone and progesterone in vitro on proliferation of human renal cell carcinomas and effects on expression of interleukin-6 or interleukin-6 receptor. J. Urol. (1995) 153(3 Pt 1):858-862.
35. PIZZOCARO G, PIVA L, DI FRONZO G et al.: Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J. Urol. (1987) 138(6):1379-1381.
36. FUJIKAWA K, MATSUI Y, MIURA K et al.: Serum immunosuppressive acidic protein and natural killer cell activity in patients with metastatic renal cell carcinoma before and after nephrectomy. J. Urol. (2000) 164(3 Pt 1):673-675.
37. DADIAN G, RICHES PG, HENDERSON DC et al.: Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br. J. Urol. (1994) 74(1):15-22.
38. MONTIE JE, STRAFFON RA, DEODHAR SD, BARNA B: In vitro assessment of cell-mediated immunity in patients with renal cell carcinoma. J. Urol. (1976) 115(3):239-242.
39. RAYMAN P, WESA AK, RICHMOND AL et al.: Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin. Cancer Res. (2004) 10(18 Pt 2):6360S-6366S.
40. MESSING EM, MANOLA J, WILDING G et al.: Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J. Clin. Oncol. (2003) 21(7):1214-1222.
41. PIZZOCARO G, PIVA L, COLAVITA M et al.: Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J. Clin. Oncol. (2001) 19(2):425-431.
42. PORZSOLT F: Adjuvant therapy of renal cell cancer (RCC) with interferon alfa-2a. Proc. Am. Soc. Clin. Oncol. (1992) 11:202 Abstract 622.
43. CLARK JI, ATKINS MB, URBA WJ et al.: Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J. Clin. Oncol. (2003) 21(16):3133-3140.
44. ATZPODIEN J, SCHMITT E, GERTENBACH U et al.: Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br. J. Cancer (2005) 92(5):843-846.
45. BLATTMAN JN, GREENBERG PD: Cancer immunotherapy: a treatment for the masses. Science (2004) 305(5681):200-205.
46. DERWEESH IH, TANNENBAUM CS, RAYMAN PA, FINKE JH: Mechanisms of immune dysfunction in renal cell carcinoma. Cancer Treat. Res. (2003) 116:29-51.
47. FEARNLEY DB, WHYTE LF, CARNOUTSOS SA, COOK AH, HART DN: Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood (1999) 93(2):728-736.
48. MEIDENBAUER N, ANDREESEN R, MACKENSEN A: Dendritic cells for specific cancer immunotherapy. Biol. Chem. (2001) 382(4):507-520.
49. RADMAYR C, BOCK G, HOBISCH A et al.: Dendritic antigen-presenting cells from the peripheral blood of renal-cell-carcinoma patients. Int. J. Cancer (1995) 63(5):627-632.
50. MULDERS P, TSO CL, GITLITZ B et al.: Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin. Cancer Res. (1999) 5(2):445-454.
51. HINKEL A, TSO CL, GITLITZ BJ et al.: Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma. J. Immunother. (2000) 23(1):83-93.
52. SAWCZUK I, ARMENTROUT S, BABAYAN R et al.: Adjuvant autolymphocyte therapy in the treatment of T 1-3a,b,c or T 4N+M0 renal cell carcinoma. J. Urol. (1998) 159(5):171 Abstract 653.
53. ADLER A, GILLON G, LURIE H et al.: Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immuno-versus hormonotherapy. Preliminary report of immunological and clinical aspects. J. Biol. Response Mod. (1987) 6(6):610-624.
54. GALLIGIONI E, QUAIA M, MERLO A et al.: Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study. Cancer (1996) 77(12):2560-2566.
55. DILLMAN R, BARTH N, VANDERMOLEN L et al.: Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma. Cancer Biother. Radiopharm. (2004) 19(5):570-580.
56. JOCHAM D, RICHTER A, HOFFMANN L et al.: Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet (2004) 363(9409):594-599.
57. ALMAND B, RESSER JR, LINDMAN B et al.: Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. (2000) 6(5):1755-1766.
58. OHM JE, GABRILOVICH DI, SEMPOWSKI GD et al.: VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood (2003) 101(12):4878-4886.
59. UPTON MP, PARKER RA, YOUMANS A, MCDERMOTT DF, ATKINS MB: Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J. Immunother. (2005) 28(5):488-495.
60. LEBRET T, WATSON RW, FITZPATRICK JM: Heat shock proteins: their role in urological tumors. J. Urol. (2003) 169(1):338-346.
61. HOOS A, LEVEY DL: Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev. Vaccines (2003) 2(3):369-379.
62. SRIVASTAVA PK, DELEO AB, OLD LJ: Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc. Natl. Acad. Sci. USA (1986) 83(10):3407-3411.
63. SRIVASTAVA PK: Immunotherapy of human cancer: lessons from mice. Nat. Immunol. (2000) 1(5):363-366.
64. TAMURA Y, PENG P, LIU K, DAOU M, SRIVASTAVA PK: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (1997) 278(5335):117-120.
65. LEWIS JJ: Therapeutic cancer vaccines: using unique antigens. Proc. Natl. Acad. Sci. USA (2004) 101(Suppl. 2):14653-14656.
66. ASSIKIS VJ, DALIANI L, PAGLIARO L et al.: Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). Proc. Am. Soc. Clin. Oncol. (2003) 22:386. Abstract 1552.
67. PALAPATTU GS, REITER RE: Monoclonal antibody therapy for genitourinary oncology: promise for the future. J. Urol. (2002) 168(6):2615-2623.
68. OOSTERWIJK E, RUITER DJ, HOEDEMAEKER PJ et al.: Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer (1986) 38(4):489-494.
69. LIAO SY, AURELIO ON, JAN K, ZAVADA J, STANBRIDGE EJ: Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. (1997) 57(14):2827-2831.
70. PASTOREK J, PASTOREKOVA S, CALLEBAUT I et al.: Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene (1994) 9(10):2877-2888.
71. IVANOV S, LIAO SY, IVANOVA A et al.: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. (2001) 158(3):905-919.
72. LONCASTER JA, HARRIS AL, DAVIDSON SE et al.: Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. (2001) 61(17):6394-6399.
73. WYKOFF CC, BEASLEYN J, WATSON PH et al.: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. (2000) 60(24):7075-7083.
74. IVANOV SV, KUZMIN I, WEI MH et al.: Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. USA (1998) 95(21):12596-12601.
75. POTTER C, HARRIS AL: Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle (2004) 3(2):164-167.
76. BLEUMER I, KNUTH A, OOSTERWIJK E et al.: A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer (2004) 90(5):985-990.
77. LIU Z, SMYTH FE, RENNER C et al.: Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol. Immunother. (2002) 51(3):171-177.
78. 2a in metastatic renal cell carcinoma patients. Proc. Am. Soc. Clin. Oncol. (2004) 23:407 Abstract 4606.
79. OOSTERWIJK E, DIVGI CR, BROUWERS A et al.: Monoclonal antibody-based therapy for renal cell carcinoma. Urol. Clin. North Am. (2003) 30(3):623-631.
80. DALIANI DD, PAPANDREOU CN, THALL PF et al.: A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer (2002) 95(4):758-765.
81. HERNBERG M, VIRKKUNEN P, BONO P et al.: Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J. Clin. Oncol. (2003) 21(20):3770-3776.
82. CHAMBERS CA, KUHNS MS, EGEN JG, ALLISON JP: CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Ann. Rev. Immunol. (2001) 19:565-594.
83. VISSERS JL, DE VRIES IJ, SCHREURS MW et al.: The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. (1999) 59(21):5554-5559.
84. VISSERS JL, DE VRIES IJ, ENGELEN LP et al.: Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes. Int. J. Cancer (2002) 100(4):441-444.
85. TSO CL, ZISMAN A, PANTUCK A et al.: Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/ monocyte-colony stimulating factor. Cancer Res. (2001) 61(21):7925-7933.
86. HERNANDEZ JM, BUI MH, HAN KR et al.: Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. Clin. Cancer Res. (2003) 9(5):1906-1916.
87. MUKOUYAMA H, JANZEN NK, HERNANDEZ JM et al.: Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. Clin. Cancer Res. (2004) 10(4):1421-1429.
88. BUI MH, SELIGSON D, HAN KR et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. (2003) 9(2):802-811.
89. ATKINS M, REGAN M, MCDERMOTT D et al.: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. (2005) 11(10):3714-3721.
90. LEPPERT JT, LAM JS, YU H et al.: Targeting the vascular endothelial growth factor pathway in renal cell carcinoma, a tissue array based analysis. J. Clin. Oncol. (2005) 23(Suppl.):386s Abstract 4536.